TVG Partners (CEO Lee Ji-sun) announced on the 15th that it has formed the 'Super Gap OI Venture Investment Association' with Celltrion, Shinshin Pharmaceutical, and Incheon Technopark to support early-stage startups in the domestic bio and healthcare sectors.
This fund, which has been raised with a total of 1.5 billion won, will be operated jointly with JNP Medi Partners and plans to focus on investing in early-stage bio and healthcare startups established less than three years ago across the country, including Incheon.
Celltrion and Shinshin Pharmaceutical will participate as limited partners (LPs) to provide open innovation opportunities to the fund's invested startups. Incheon Technopark will also participate as an LP to support the development of a regional bio cluster. JNP Medi Partners will provide consulting services on technology commercialization and clinical trial design, leveraging its parent company's experience in clinical trial lifecycle services, including AI clinical trial platforms.
TVG Partners has been promoting open innovation in collaboration with Celltrion since 2020, and this year, it is conducting an open innovation program with Celltrion and Shinshin Pharmaceutical in Gyeonggi-do and Chungcheongbuk-do.
Lee Ji-sun, CEO of TVG Partners, said, “Our goal is to discover promising companies in the bio and healthcare sectors, help them grow quickly, and enhance the competitiveness of the domestic industry.” He added, “We will build a startup growth infrastructure, including PoC (proof of concept) and technical support through open innovation.”
Meanwhile, TVG Partners has been supporting the overseas expansion of domestic bio and healthcare startups by hosting the 'Connect' event in Singapore every year since 2022, with the participation of global companies, investors, and related organizations.
You must be logged in to post a comment.